Originally broadcast October 9, 2025
$44 billion in drugs that help Americans are purchased through a little-known federal discount program called 340B. The program is recognized for successfully helping hospitals, community health centers and others that fund care for low-income patients.
But that program is now facing big challenges from drugmakers, and the current government shutdown has brought new uncertainty.
Reporter William Newton of 340B Report tells hosts Mark Masselli and Margaret Flinter that the shutdown has delayed approvals for a federal rebate pilot and furloughed key staff. “There are a lot of big question marks,” he says, noting that the delays could jeopardize timelines for hospitals and community clinics that depend on 340B savings.
David Lim of POLITICO adds perspective on how drug manufacturers and policymakers are shaping the future of the 340B program. Together, he and Newton explain how what began as a quiet effort to help safety-net providers has grown into a national discussion about drug prices and access to care.
As Newton explains, “The 340B program may sound niche, but it’s actually the second-largest government prescription drug program, touching every corner of the U.S. health-care system.”
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Spotify | Android | Podchaser | TuneIn | RSS | More
Originally broadcast October 2, 2025 The federal government is shut down and the ripple effects…
Originally broadcast Tuesday, September 23, 2025 Happy anniversary to “Conversations on Health Care”! We posted…
Dr. Wayne Jonas, who formerly led the National Institutes of Health Office of Alternative Medicine,…
Next week former Centers for Disease Control and Prevention Director Susan Monarez will testify in…
Supporters say Health and Human Services Secretary Robert F. Kennedy, Jr. is fulfilling his vision…
Originally broadcast Wednesday, August 27 Dr. Victor Montori, a Mayo Clinic endocrinologist, internationally recognized researcher,…